Cardiovascular Drugs and Therapy

, Volume 21, Issue 2, pp 121-132

First online:

Pharmacogenomics of Renin Angiotensin System Inhibitors in Coronary Artery Disease

  • James P. TsikourisAffiliated withSchool of Pharmacy, University of Pittsburgh Email author 
  • , Michael J. PeetersAffiliated withCollege of Pharmacy, University of Toledo

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Renin Angiotensin System (RAS) inhibitors comprise some of the most commonly used medications in coronary artery disease (CAD) and its related syndromes. Unfortunately, significant inter-patient variability seems likely in response to these agents; of which, the influence of genetic determinants is of interest. This review summarizes the available RAS inhibitor pharmacogenomic studies which have evaluated RAS polymorphisms that either elucidate mechanism via surrogate endpoint measurements, or predict efficacy via clinical outcomes in CAD related syndromes.Regardless of the endpoint, none of the RAS genotypes conclusively predicts efficacy of RAS inhibitors. In fact, the results of the pharmacogenomic studies were often in direct conflict with one another. Varied results appear due to methodological limitations (e.g., inadequate study power, genotyping error, methods of endpoint measurement), study conceptualization (e.g., overestimating the contribution of polymorphism to disease, lack of haplotype approach), and differences between studies (e.g., genotype frequency, study subject characteristics, the specific medication and dose used). Thus investigators should consider the various methodological limitations to improve upon the current approach to RAS inhibitor pharmacogenomic research in the vast CAD population.

Key words

pharmacogenomic renin angiotensin system ACE Inhibitor angiotensin II type-1 receptor blocker